吉西他滨联合卡铂治疗非小细胞肺癌疗效观察  

Combination of Gemcitabine and Carboplatin in the Treatment of Patients with Non-smallCell Lung Cancer

作　　者：程先鸣 王红民[1] 余意[1] 潘伟 倪荣清 

机构地区：[1]汉口铁路医院肿瘤科,武汉430012

出　　处：《肿瘤防治研究》2006年第6期442-443,共2页Cancer Research on Prevention and Treatment

摘　　要：目的观察吉西他滨联合卡铂治疗非小细胞肺癌的疗效及毒性反应。方法经病理组织学或细胞学证实的48例非小细胞肺癌患者给予吉西他滨1000mg/m2静滴,第1,8天,卡铂AUC5静滴,第1天,3周为1周期。结果可评价疗效48例,有效率为52%,毒副反应主要为白细胞及血小板降低,但均可耐受。结论吉西他滨联合卡铂治疗非小细胞肺癌具有较好的疗效,且毒性反应可以耐受。Objective To observe the efficacy, toxicity and side effects of the combination of gemcitabine and carboplatin in the treatment of patients with non-small cell lung cancer（NSCLC）. Methods 48 patients with NSCLC diagnosed by pathology or cytology were enrolled into the study. The patients received gemcitabine 1 000mg/m^2 on d1,8 and carboplatin AUC 5 on dl of the 21-day cycle （3-week regiment）. Results 48 of all the cases could be evaluated. The response rate was 52%. The major toxicity and side effects included leucopenia and thromasthenia, but they were acceptable. Conclusion The combination of gemcitabine and carboplatin is an effective and tolerable regiment in the treatment of NSCLC.

关 键 词：肺肿瘤 吉西他滨 卡铂 化疗 

分 类 号：R730.53[医药卫生—肿瘤]